Preclinical safety evaluation and tracing of human mesenchymal stromal cell spheroids following intravenous injection into cynomolgus monkeys

Abstract

We have previously demonstrated that mesenchymal stromal/stem cells (MSCs) in spheroids (MSC_sp) tolerate ambient and hypoxic conditions for a prolonged time. Local administration of MSC_sp, but not dissociated MSCs (MSC_diss), promotes wound healing and relieves multiple sclerosis and osteoarthritis in mice and monkeys. These findings indicate an advantage of MSC_sp over MSC_diss in sustaining cell viability and efficacy following transplantation, which, however, does not appear to apply to intravenous (i.v.) injection for the principal concern that MSC_sp might cause embolism in small blood vessels of the host, leading to sudden death. Here, we addressed this concern by injecting human MSC_sp (∼450 μm) or MSC_diss i.v. into cynomolgus monkeys. Surprisingly, no deaths occurred until sacrifice at day 21 or 60 post injection, and no remarkable physiological changes were found in the animals following the i.v. injection. The big diameters of large blood vessels in monkeys, compared to small animals like mice, may allow sufficient time for MSC_sp to dissociate into single cells so they can pass through small vessels without causing embolism. Retention of MSC_sp was lower in the lungs but higher in the blood than retention of MSC_diss at 1 h post injection and both disappeared at day 21. In vitro, MSC_sp tolerated fluidic shear stress with higher survival than MSC_diss. Thus, i.v. injection of MSC_sp into nonhuman primates is feasible, safe, and probably associated with better survival, less lung entrapment and higher efficacy than administration of MSC_diss.